Wolfe Research upgraded Nevro from Underperform to Peer Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/10/2025 | $4.50 → $5.85 | Underperform → Hold | Jefferies |
| 2/7/2025 | $6.00 → $5.85 | Neutral → Overweight | Piper Sandler |
| 12/3/2024 | $5.00 | Equal Weight | Wells Fargo |
| 12/2/2024 | $9.00 → $4.00 | Equal-Weight → Underweight | Morgan Stanley |
| 8/9/2024 | Sell → Neutral | Citigroup | |
| 8/8/2024 | Underperform → Peer Perform | Wolfe Research | |
| 8/7/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 8/7/2024 | Neutral → Underweight | JP Morgan |
4 - NEVRO CORP (0001444380) (Issuer)
4 - NEVRO CORP (0001444380) (Issuer)
4 - NEVRO CORP (0001444380) (Issuer)
Appoints Kirt P. Karros to Board of Directors REDWOOD CITY, Calif., Feb. 21, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has entered into a Cooperation Agreement with Engaged Capital, LLC ("Engaged Capital"), pursuant to which Kirt P. Karros has been appointed to Nevro's Board of Directors ("the Board") as well as the Audit Committee of the Board effective February 20, 2024. Mr. Karros is an accomplished finance executive with extensive experience in finance, including capital allocation and financial planning and analysis, as well as strategi
REDWOOD CITY, Calif., April 19, 2021 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the appointment of Jon Shear to the newly created position of Vice President, Corporate Development, effective immediately. "Jon is uniquely qualified for this new role and brings extensive insight and understanding of the medical technologies industry to Nevro," said D. Keith Grossman, Chairman, CEO and President of Nevro. "As a member of our leadership team, he will be responsible for leading Nevro's strategic planning process, overseeing the business development function and
REDWOOD CITY, Calif., Nov. 30, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that Julie Dewey has joined the company as vice president, investor relations and corporate communications, effective immediately. "Julie has a tremendous depth of experience in all areas of investor relations and corporate communications, a deep knowledge of capital markets and has earned an outstanding reputation within the investment community," said Rod MacLeod, CFO of Nevro. "As a member of our leadership team, she will be instrumental in communicating the Nevro story a
Jefferies upgraded Nevro from Underperform to Hold and set a new price target of $5.85 from $4.50 previously
Piper Sandler upgraded Nevro from Neutral to Overweight and set a new price target of $5.85 from $6.00 previously
Wells Fargo initiated coverage of Nevro with a rating of Equal Weight and set a new price target of $5.00